Drug Information

General Information
Drug ID
DR01270
Drug Name
Ibrutinib
Synonyms
Ibrutinib (BTK inhibitor); PCI-32765
Drug Type
Small molecular drug
Indication Chronic lymphocytic leukemia [ICD11: 2A82.0] Approved [1]
Mantle cell lymphoma [ICD11: 2A85.5] Approved [1]
Waldenstrom's macroglobulinemia [ICD11: 2A85.4] Approved [1]
Structure
3D MOL 2D MOL
Formula
C25H24N6O2
Canonical SMILES
C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N
InChI
InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1
InChIKey
XYFPWWZEPKGCCK-GOSISDBHSA-N
CAS Number
CAS 936563-96-1
Pharmaceutical Properties Molecular Weight 440.5 Topological Polar Surface Area 99.2
Heavy Atom Count 33 Rotatable Bond Count 5
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 6
XLogP
3.6
PubChem CID
24821094
PubChem SID
49837088 , 57132050 , 123051065 , 124898784 , 124898785 , 136940589 , 136961336 , 137472671 , 152258295 , 160647134 , 162202692 , 163312254 , 163679284 , 164045821 , 164193915 , 165245631 , 171572071 , 172919350 , 174007139 , 175267389 , 176250273 , 178103494 , 184611713 , 184816969 , 189025882 , 198993428 , 215784879 , 223375297 , 223485070 , 223600477 , 223685684 , 223704724 , 224184328 , 226558356 , 242585660 , 247523488 , 249736825 , 251971042 , 252088605 , 252110183 , 252160516 , 252215999 , 252451849
ChEBI ID
CHEBI:76612
TTD Drug ID
D09KTS
DT(s) Transporting This Drug P-GP Transporter Info P-glycoprotein 1 Substrate [2]
References
1 Ibrutinib was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability. Mol Pharm. 2018 Nov 5;15(11):5124-5134.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.